Treats relapsing forms of multiple sclerosis (MS). ANDA 203857, held by Synthon BV. Glatiramer Acetate.
As of Nov 16, 2026, ANDA 203857 (Glatiramer Acetate), held by Synthon BV, was first approved by FDA on Sep 25, 2024, with 1 approved supplement and 0 published complete response letters.
Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 25, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Glatiramer Acetate20MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
| May 16, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 25, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters